$8.43
6.04% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US50127T1097
Symbol
KURA

Kura Oncology, Inc. Stock price

$8.43
+2.11 33.39% 1M
+1.18 16.28% 6M
-0.28 3.21% YTD
-11.78 58.29% 1Y
-6.37 43.04% 3Y
-15.47 64.73% 5Y
-6.57 43.80% 10Y
-6.57 43.80% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.48 6.04%
ISIN
US50127T1097
Symbol
KURA
Industry

Key metrics

Basic
Market capitalization
$731.7m
Enterprise Value
$110.6m
Net debt
positive
Cash
$630.7m
Shares outstanding
86.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.8 | 8.5
EV/Sales
1.3 | 1.3
EV/FCF
0.9
P/B
2.4
Financial Health
Equity Ratio
54.4%
Return on Equity
-42.1%
ROCE
-38.2%
ROIC
-39,684.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$83.3m | $86.3m
EBITDA
$-218.8m | $-238.8m
EBIT
$-219.7m | $-247.1m
Net Income
$-197.2m | $-223.8m
Free Cash Flow
$122.9m
Growth (TTM | estimate)
Revenue
- | 60.3%
EBITDA
-9.8% | -24.1%
EBIT
-9.8% | -27.9%
Net Income
-8.5% | -28.6%
Free Cash Flow
179.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-262.8% | -276.5%
EBIT
-263.8%
Net
-236.8% | -259.2%
Free Cash Flow
147.5%
More
EPS
$-2.3
FCF per Share
$1.4
Short interest
9.2%
Employees
192
Rev per Employee
$280.0k
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Kura Oncology, Inc. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
83 83
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 90 90
45% 45%
108%
- Research and Development Expense 213 213
54% 54%
255%
-219 -219
10% 10%
-263%
- Depreciation and Amortization 0.88 0.88
1% 1%
1%
EBIT (Operating Income) EBIT -220 -220
10% 10%
-264%
Net Profit -197 -197
8% 8%
-237%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
about 18 hours ago
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
Neutral
GlobeNewsWire
7 days ago
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.
Neutral
Seeking Alpha
25 days ago
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leoni - Chief Medical Officer Thomas Doyle - Senior Vice President of Finance & Accounting Troy Edward Wilson - Chairman, CEO & President Conference Call Participants Ellen Horste - TD Cowen, Research...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today